Gut microbiota of miR-30a-5p-deleted mice aggravate high-fat diet-induced hepatic steatosis by regulating arachidonic acid metabolic pathway

Abstract

MiR-30a-5p deletion aggravated hepatic steatosis and lipid disorder induced by an HFD in mice. Gut microbiota participated in the regulation of hepatic steatosis in the context of miR-30a-5p. Gut microbiota metabolism-related arachidonic acid metabolic pathway contributed to miR-30a-5p-regulated hepatic steatosis and lipid disorder. Reintroducing miR-30a-5p reversed hepatic steatosis and arachidonic acid metabolism disorder caused by HFD and miR-30a-5p deletion.

Keywords

arachidonic acid metabolism / COX/LOX pathways / gut microbiota / hepatic steatosis / miR-30a-5p

References

[1] LeeNY, YoonSJ, HanDH, et al. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020; 11: 882-899.

[2] KoningM, Herrema H, NieuwdorpM, MeijnikmanAS. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies. Gut Microbes. 2023; 15: 2226922.

[3] ChenML, YiL, ZhangY, et al. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. mBio. 2016; 7: e02210-02215.

[4] LuoL, ChangY, ShengL. Gut-liver axis in the progression of nonalcoholic fatty liver disease: from the microbial derivatives-centered perspective. Life Sci. 2023; 321: 121614.

[5] YangL, HaoY, BoeckmansJ, Rodrigues RM, HeY. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: novel therapeutic targets. Pharmacol Ther. 2023; 243: 108353.

[6] MaciejakA, Kostarska-Srokosz E, GierlakW, et al. Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction. Sci Rep. 2018; 8: 9883.

[7] MaW, QiuZ, BaiZ, et al. Inhibition of microRNA-30a alleviates vascular remodeling in pulmonary arterial hypertension. Mol Ther – Nucl Acids. 2021; 26: 678-693.

[8] ZhangX, GaoY, WuH, MaoY, QiY. LncRNA HOX transcript antisense RNA mitigates cardiac function injury in chronic heart failure via regulating microRNA-30a-5p to target KDM3A. J Cell Mol Med. 2022; 26: 1473-1485.

[9] LiuX, DouB, TangW, et al. Cardioprotective effects of circ_0002612 in myocardial ischemia/reperfusion injury correlate with disruption of miR-30a-5p-dependent Ppargc1a inhibition. Int Immunopharmacol. 2023; 117: 110006.

[10] JiangW, ShiX, SunL, et al. Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner. Int J Biol Sci. 2023; 19: 4571-4587.

[11] BehuraA, MishraA, ChughS, et al. ESAT-6 modulates calcimycin-induced autophagy through microRNA-30a in mycobacteria infected macrophages. J Infect. 2019; 79: 139-152.

[12] ZhaoX, KongX, CuiZ, et al. Communication between nonalcoholic fatty liver disease and atherosclerosis: focusing on exosomes. Eur J Pharm Sci. 2024; 193: 106690.

[13] El HageR, Al-Arawe N, HinterseherI. The role of the gut microbiome and trimethylamine oxide in atherosclerosis and age-related disease. Int J Mol Sci. 2023; 24: 2399.

[14] YuJS, YounGS, ChoiJ, et al. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease. Clin Transl Med. 2021; 11: e634.

[15] SongF, LiJ-Z, WuY, WuW-Y, WangY, Li G. Ubiquitinated ligation protein NEDD4L participates in MiR-30a-5p attenuated atherosclerosis by regulating macrophage polarization and lipid metabolism. Mol Ther – Nucl Acids. 2021; 26: 1303-1317.

[16] CaniPD, Depommier C, DerrienM, EverardA, de VosWM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol. 2022; 19: 625-637.

[17] YanJ, ShengL, LiH. Akkermansia muciniphila: is it the Holy Grail for ameliorating metabolic diseases?. Gut Microbes. 2021; 13: 1984104.

[18] DuellPB, WeltyFK, MillerM, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022; 42: e168-e185.

[19] LoombaR, Friedman SL, ShulmanGI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021; 184: 2537-2564.

[20] SygitowiczG, Maciejak-Jastrzębska A, SitkiewiczD. MicroRNAs in the development of left ventricular remodeling and postmyocardial infarction heart failure. Polish Arch Int Med. 2020; 130: 59-65.

[21] PordzikJ, Jakubik D, Jarosz-PopekJ, et al. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review. Cardiovasc Diabetol. 2019; 18: 113.

[22] MaM, LuoQ, FanL, et al. The urinary exosomes derived from premature infants attenuate cisplatin-induced acute kidney injury in mice via microRNA-30a-5p/mitogen-activated protein kinase 8 (MAPK8). Bioengineered. 2022; 13: 1650-1665.

[23] ZhangC, GanX, LiangR, Jian J. Exosomes derived from epigallocatechin gallate-treated cardiomyocytes attenuated acute myocardial infarction by modulating MicroRNA-30a. Front Pharmacol. 2020; 11: 120.

[24] ZhangZ, TanX, LuoJ, YaoH, SiZ, TongJS. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis. 2020; 11: 902.

[25] TilgH, AdolphTE, TraunerM. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022; 34: 1700-1718.

[26] LuoT, GuoZ, LiuD, et al. Deficiency of PSRC1 accelerates atherosclerosis by increasing TMAO production via manipulating gut microbiota and flavin monooxygenase 3. Gut Microbes. 2022; 14: 2077602.

[27] MeijnikmanAS, DavidsM, HerremaH, et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med. 2022; 28: 2100-2106.

[28] MengQ, MaM, ZhangW, et al. The gut microbiota during the progression of atherosclerosis in the perimenopausal period shows specific compositional changes and significant correlations with circulating lipid metabolites. Gut Microbes. 2021; 13: 1880220.

[29] RodriguesVF, Elias-Oliveira J, PereiraíS, et al. Akkermansia muciniphila and gut immune system: a good friendship that attenuates inflammatory bowel disease, obesity, and diabetes. Front Immunol. 2022; 13: 934695.

[30] BaeM, Cassilly CD, LiuX, et al. Akkermansia muciniphila phospholipid induces homeostatic immune responses. Nature. 2022; 608: 168-173.

[31] ZhouY, KhanH, XiaoJ, Cheang WS. Effects of arachidonic acid metabolites on cardiovascular health and disease. Int J Mol Sci. 2021; 22: 12029.

[32] BadimonL, Vilahur G, RoccaB, PatronoC. The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. Cardiovasc Res. 2021; 117: 2001-2015.

[33] SonnweberT, Pizzini A, NairzM, WeissG, Tancevski I. Arachidonic acid metabolites in cardiovascular and metabolic diseases. Int J Mol Sci. 2018; 19: 3285.

[34] WangB, WuL, ChenJ, et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Targeted Ther. 2021; 6: 94.

[35] HannaVS, HafezEAA. Synopsis of arachidonic acid metabolism: a review. J Adv Res. 2018; 11: 23-32.

[36] ChenQ, LuoY, ShenY, et al. Fructose corn syrup induces inflammatory injury and obesity by altering gut microbiota and gut microbiota-related arachidonic acid metabolism. J Nutr Biochem. 2024; 124: 109527.

[37] DemetzE, Schroll A, AuerK, et al. The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab. 2014; 20: 787-798.

[38] HuWM, LiuSQ, ZhuKF, et al. The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK/STAT and inhibits pancreatic cancer invasion and metastasis. Int Immunopharmacol. 2023; 121: 110505.

[39] YangF, ZhangY, RenH, et al. Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis. J Exp Clin Cancer Res: CR. 2019; 38: 489.

[40] TakJ, KimYS, KimTH, Park GC, HwangS, KimSG. Galpha(12) overexpression in hepatocytes by ER stress exacerbates acute liver injury via ROCK1-mediated miR-15a and ALOX12 dysregulation. Theranostics. 2022; 12: 1570-1588.

[41] ZhongC, YangJ, ZhangY, et al. TRPM2 mediates hepatic ischemia-reperfusion injury via Ca(2+)-induced mitochondrial lipid peroxidation through increasing ALOX12 expression. Research. 2023; 6: 0159.

[42] YuQ, LiC, NiuQ, et al. Hepatic COX1 loss leads to impaired autophagic flux and exacerbates nonalcoholic steatohepatitis. Acta Pharmaceutica Sinica B. 2023; 13: 2628-2644.

[43] XiaoJ, LiongEC, HuangH, et al. Cyclooxygenase-1 serves a vital hepato-protective function in chemically induced acute liver injury. Toxicol Sci. 2015; 143: 430-440.

[44] GrauperaM, Garcia-Pagan JC, ParesM, et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol. 2003; 39: 515-521.

[45] SaraswathiV, Ramnanan CJ, WilksAW, et al. Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic disorders in mice. Metabolism. 2013; 62: 1673-1685.

[46] ChenH, CaiW, ChuESH, et al. Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene. 2017; 36: 4415-4426.

[47] ChenY, ChenHN, WangK, et al. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol. 2019; 70: 66-77.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.